AbbVie - 14 Year Stock Price History | ABBV
Historical daily share price chart and data for AbbVie since 2012 adjusted for splits and dividends. The latest closing stock price for AbbVie as of June 12, 2026 is 227.73.
- The all-time high AbbVie stock closing price was 238.71 on October 01, 2025.
- The AbbVie 52-week high stock price is 244.81, which is 7.5% above the current share price.
- The AbbVie 52-week low stock price is 181.73, which is 20.2% below the current share price.
- The average AbbVie stock price for the last 52 weeks is 215.02.
| AbbVie Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 215.5528 | 225.6080 | 234.2470 | 197.3800 | 227.7300 | 1.30% |
| 2025 | 197.4652 | 170.5790 | 238.7140 | 162.3610 | 224.8010 | 33.08% |
| 2024 | 166.1976 | 146.5610 | 193.8020 | 144.6430 | 168.9250 | 18.87% |
| 2023 | 133.5190 | 143.1270 | 148.0790 | 118.9930 | 142.1130 | -0.24% |
| 2022 | 129.0780 | 114.8870 | 149.9720 | 113.1310 | 142.4480 | 24.01% |
| 2021 | 94.1823 | 85.3343 | 115.3200 | 83.7852 | 114.8700 | 32.43% |
| 2020 | 72.1065 | 68.6921 | 87.9734 | 50.1452 | 86.7429 | 27.72% |
| 2019 | 58.4193 | 64.7855 | 69.2291 | 47.6164 | 67.9174 | 1.47% |
| 2018 | 69.5416 | 68.7690 | 86.7169 | 56.5231 | 66.9346 | -0.96% |
| 2017 | 51.9252 | 42.0768 | 68.6293 | 40.8601 | 67.5811 | 60.07% |
| 2016 | 40.3257 | 37.3950 | 45.0192 | 33.5702 | 42.2184 | 9.79% |
| 2015 | 39.7697 | 41.4085 | 45.8121 | 31.3324 | 38.4531 | -6.50% |
| 2014 | 34.4535 | 31.6447 | 43.8092 | 28.7353 | 41.1257 | 27.92% |
| 2013 | 26.2264 | 20.5594 | 33.0693 | 19.7340 | 32.1500 | 60.77% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $367.673B | $61.160B |
| AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |